SRAM
TTNP

Stone Ridge Asset Management’s Titan Pharmaceuticals TTNP Stock Holding History

Stone Ridge Asset Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8
Closed -$30K – 1327
2018
Q1 		$30K Sell
8
-1
-11% -$4.18K ﹤0.01% 1332
2017
Q4 		$41K Buy
+9
New +$56K ﹤0.01% 1353

Other funds holding TTNP

CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Stone Ridge Asset Management's TTNP Position: Q2 2018 in Review

Stone Ridge Asset Management sold out of Titan Pharmaceuticals (TTNP) in Q2 2018, closing a stake of 8 shares — an estimated $30K sold.

Stone Ridge Asset Management first reported a position in TTNP in Q4 2017 and held it in 2 quarters. The position peaked at $41K in Q4 2017. 21 funds tracked by Wall St. Rank hold TTNP as of Q2 2018.

  • Stone Ridge Asset Management reported no remaining Titan Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 8 Titan Pharmaceuticals shares in Q2 2018, an estimated $30K.
  • Stone Ridge Asset Management first reported a position in Titan Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Stone Ridge Asset Management's Titan Pharmaceuticals position peaked at $41K in Q4 2017.
  • 21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2018.

Based on Stone Ridge Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.